Table 1.
Subject Demographics
| AGE±S.D.a | % F b | Therapy c | CD14 d | CD4 | CD8A | CD19 | CD56 | FCGR3A | |
|---|---|---|---|---|---|---|---|---|---|
| UC | 30±4 | 67 | + | 0.95 | 0.83 | 0.85 | 0.86 | 0.88 | 0.98 |
| Cr | 31±4 | 67 | + | 0.86 | 0.81 | 0.83 | 0.76 | 1.06 | 0.86 |
| Ce | 38±5 | 67 | + | 1.03 | 0.96 | 1.06 | 1.04 | 0.94 | 1.09 |
| IBS | 37±4 | 83 | − | 1.05 | 0.88 | 0.81 | 0.85 | 0.98 | 1.17 |
| FMS | 43±4 | 83 | − | 1.22 | 1.24 | 1.21 | 1.21 | 1.07 | 0.89 |
| MS-C | 32±3 | 67 | − | 1.29 | 1.03 | 0.81 | 1.14 | 1.09 | 1.02 |
| MS-N | 34±3 | 83 | − | 1.26 | 1.04 | 0.88 | 1.16 | 0.89 | 1.13 |
| MS-E | 39±3 | 67 | + | 1.08 | 0.84 | 0.86 | 0.80 | 1.09 | 1.05 |
| HC | 38±11 | 75 | − | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| RA-MTX | 47±4 | 67 | + | 0.96 | 1.06 | 0.93 | 1.27 | 1.11 | 1.14 |
| RA+MTX | 48±5 | 83 | + | 0.93 | 0.89 | 0.83 | 0.80 | 0.97 | 1.11 |
| SLE | 36±5 | 83 | + | 1.15 | 1.05 | 1.23 | 1.11 | 0.86 | 1.09 |
| Ps | 38±4 | 67 | + | 0.91 | 0.87 | 1.21 | 1.30 | 1.15 | 0.82 |
| PsA | 43±5 | 67 | + | 0.90 | 1.17 | 0.94 | 1.25 | 0.86 | 1.06 |
| Sj | 48±5 | 67 | + | 1.26 | 0.90 | 0.90 | 0.89 | 1.06 | 1.17 |
a
average age ± standard deviation, P>0.05 compared to HC
b
P>0.05 compared to HC, all subjects were Caucasian
c
Except for the RA±MTX group, subjects within each disease group were not on the same treatment therapies in an attempt to reduce effects treatments may have on RNA profiles.
d
from RNA-seq data, ratios of expression of the different cell-type specific cell surface markers in each disease cohort compared to HC, P>0.05 compared to HC; CD14, monocytes; CD4, helper T cells; CD8A, cytotoxic T cells; CD19, B cells; CD56, NK cells; FCGR3A, CD16, neutrophils.